Theriva Biologics (NYSEAMERICAN:TOVX) Issues Earnings Results

Theriva Biologics (NYSEAMERICAN:TOVX) released its quarterly earnings results on Tuesday. The company reported ($6.81) earnings per share (EPS) for the quarter, missing the consensus estimate of ($6.25) by ($0.56), Zacks reports.

Theriva Biologics Stock Down 4.1 %

Shares of TOVX traded down $0.06 during mid-day trading on Thursday, reaching $1.36. The company’s stock had a trading volume of 105,323 shares, compared to its average volume of 1,002,174. The stock has a market cap of $3.09 million, a price-to-earnings ratio of -0.04 and a beta of 1.34. Theriva Biologics has a 1-year low of $1.24 and a 1-year high of $17.11.

Analysts Set New Price Targets

Separately, Maxim Group decreased their price target on shares of Theriva Biologics from $25.00 to $6.00 and set a “buy” rating for the company in a research note on Wednesday.

About Theriva Biologics

Theriva Biologics, Inc, a clinical-stage company, develops therapeutics to treat cancer and related diseases in areas of high unmet need in the United States. The company’s lead product candidate is VCN-01, a clinical stage oncolytic human adenovirus that is in a Phase 2 clinical study for the treatment of pancreatic cancer; a Phase 1 clinical study for the treatment of retinalblastoma; a Phase 1 clinical study for the treatment of head and neck squamous cell carcinoma; and a Phase 1 clinical study for the treatment of solid tumors.